These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma. Procopio G; Verzoni E; de Braud F Oncology; 2013; 84(1):39-42. PubMed ID: 23076302 [No Abstract] [Full Text] [Related]
43. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors. Bukowski RM Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708 [No Abstract] [Full Text] [Related]
44. Sarcomatoid chromophobe renal cell carcinoma with osteosarcoma-like differentiation which presented as a retroperitoneal mass: a case report. Sari A; Evcım G; Ermete M; Gür S Turk Patoloji Derg; 2011 May; 27(2):164-8. PubMed ID: 21630206 [TBL] [Abstract][Full Text] [Related]
45. Editorial comment on: Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Staehler M Eur Urol; 2009 Mar; 55(3):678. PubMed ID: 18450364 [No Abstract] [Full Text] [Related]
46. Clinical significance and predictive value of prostaglandin E2 receptors (EPR) 1 - 4 in patients with renal cell carcinoma. Ohba K; Miyata Y; Watanabe S; Hayashi T; Kanetake H; Kanda S; Sakai H Anticancer Res; 2011 Feb; 31(2):597-605. PubMed ID: 21378344 [TBL] [Abstract][Full Text] [Related]
47. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. Kugler A; Hemmerlein B; Thelen P; Kallerhoff M; Radzun HJ; Ringert RH J Urol; 1998 Nov; 160(5):1914-8. PubMed ID: 9783985 [TBL] [Abstract][Full Text] [Related]
48. CD151 expression can predict cancer progression in clear cell renal cell carcinoma. Yoo SH; Lee K; Chae JY; Moon KC Histopathology; 2011 Jan; 58(2):191-7. PubMed ID: 21323946 [TBL] [Abstract][Full Text] [Related]
49. Prognostic and biological significance of lymph node spreading in renal cell carcinoma. Patard JJ Eur Urol; 2006 Feb; 49(2):220-2. PubMed ID: 16426737 [No Abstract] [Full Text] [Related]
50. Implications of insulin-like growth factors in renal cell carcinoma. Bennington JL; Strathearn M; Spencer EM; Williams RD Eur Urol; 1990; 18 Suppl 2():13-4. PubMed ID: 2226595 [No Abstract] [Full Text] [Related]
51. [Lectin binding studies of the human nephron and renal cell carcinoma]. Chan YF Nihon Hinyokika Gakkai Zasshi; 1986 Sep; 77(9):1405-15. PubMed ID: 3807085 [No Abstract] [Full Text] [Related]
52. Re: Zhu et al.: The expression and evaluation of androgen receptor in human renal cell carcinoma (Urology 2014;83:510.e19-24). Putz J; Wirth MP; Froehner M; Jahn S Urology; 2014 Sep; 84(3):734-5. PubMed ID: 25168563 [No Abstract] [Full Text] [Related]
53. Reply by the authors. Zhu G; Li L; He D; Chang C Urology; 2014 Sep; 84(3):735. PubMed ID: 25168565 [No Abstract] [Full Text] [Related]
54. Medical aspects of renal carcinoma. PINALS RS; KRANE SM Postgrad Med J; 1962 Sep; 38(443):507-19. PubMed ID: 14486698 [No Abstract] [Full Text] [Related]
55. [A case of renal cell carcinoma of horseshoe kidney that produced AFP and caused hypercalcemia]. Okada H; Kawabata G; Kamidono S; Ishigami J; Nakatsuka E Hinyokika Kiyo; 1984 Oct; 30(10):1453-8. PubMed ID: 6084418 [TBL] [Abstract][Full Text] [Related]
56. [Heterogeneity of human renal cell carcinoma. III. 1 alpha,25-dihydroxyvitamin D3 receptor and inhibition on the growth of renal carcinoma cell lines]. Nagakura K Nihon Hinyokika Gakkai Zasshi; 1986 Jan; 77(1):92-7. PubMed ID: 3014194 [No Abstract] [Full Text] [Related]
59. [Medical perspectives of metabolomics: the example of renal carcinoma]. Dormoy V; Massfelder T Med Sci (Paris); 2013 May; 29(5):463-8. PubMed ID: 23732093 [No Abstract] [Full Text] [Related]